Limits...
Breast cancer mortality in participants of the Norwegian Breast Cancer Screening Program.

Hofvind S, Ursin G, Tretli S, Sebuødegård S, Møller B - Cancer (2013)

Bottom Line: The MRRs were adjusted for calendar period, attained age, years since inclusion in the cohorts, and self-selection bias.The mortality reduction associated with attendance in the program was 43% (MRR, 0.57; 95% confidence interval, 0.51-0.64) after adjusting for calendar period, attained age, years after inclusion in the cohort, and self-selection bias.After 15 years of follow-up, a 43% reduction in mortality was observed among women who attended the national mammographic screening program in Norway.

View Article: PubMed Central - PubMed

Affiliation: Department of Research, Cancer Registry of Norway, Oslo, Norway; Oslo and Akershus University College of Applied Sciences, Oslo, Norway.

Show MeSH

Related in: MedlinePlus

The number of women invited and screened in the Norwegian Breast Cancer Screening Program from 1996 to 2009, exclusions, and final study cohorts, including women-years, the number of breast cancer cases, and the number of breast cancer deaths from 1996 to 2010. DCIS indicates ductal carcinoma in situ.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4288930&req=5

fig01: The number of women invited and screened in the Norwegian Breast Cancer Screening Program from 1996 to 2009, exclusions, and final study cohorts, including women-years, the number of breast cancer cases, and the number of breast cancer deaths from 1996 to 2010. DCIS indicates ductal carcinoma in situ.

Mentions: The NBCSP is administered by the Cancer Registry of Norway and targets women ages 50 to 69 years.14 The program started in 4 of 19 counties in 1996 and became nationwide in 2005. The program is run according to European guidelines.15 Each woman in the target group receives a personal letter inviting her to undergo 2-view mammography screening every second year, regardless of her cancer history (Fig. 1).


Breast cancer mortality in participants of the Norwegian Breast Cancer Screening Program.

Hofvind S, Ursin G, Tretli S, Sebuødegård S, Møller B - Cancer (2013)

The number of women invited and screened in the Norwegian Breast Cancer Screening Program from 1996 to 2009, exclusions, and final study cohorts, including women-years, the number of breast cancer cases, and the number of breast cancer deaths from 1996 to 2010. DCIS indicates ductal carcinoma in situ.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4288930&req=5

fig01: The number of women invited and screened in the Norwegian Breast Cancer Screening Program from 1996 to 2009, exclusions, and final study cohorts, including women-years, the number of breast cancer cases, and the number of breast cancer deaths from 1996 to 2010. DCIS indicates ductal carcinoma in situ.
Mentions: The NBCSP is administered by the Cancer Registry of Norway and targets women ages 50 to 69 years.14 The program started in 4 of 19 counties in 1996 and became nationwide in 2005. The program is run according to European guidelines.15 Each woman in the target group receives a personal letter inviting her to undergo 2-view mammography screening every second year, regardless of her cancer history (Fig. 1).

Bottom Line: The MRRs were adjusted for calendar period, attained age, years since inclusion in the cohorts, and self-selection bias.The mortality reduction associated with attendance in the program was 43% (MRR, 0.57; 95% confidence interval, 0.51-0.64) after adjusting for calendar period, attained age, years after inclusion in the cohort, and self-selection bias.After 15 years of follow-up, a 43% reduction in mortality was observed among women who attended the national mammographic screening program in Norway.

View Article: PubMed Central - PubMed

Affiliation: Department of Research, Cancer Registry of Norway, Oslo, Norway; Oslo and Akershus University College of Applied Sciences, Oslo, Norway.

Show MeSH
Related in: MedlinePlus